NLRC5 and melanoma: Moreover, high MHC-I expression has been proposed as a predictor of ICB response 28–31, and high expression of MHC-I and other APP genes, including NLRC5 and TAP1, correlates with better survival in patients with melanoma (Fig S5A), for whom ICB is a first-line therapy.